

1624
ifw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE: Application of Giuseppe ALVARO et al.

Serial No.: 10/089,964

Art Unit: 1624

Filing Date: May 8, 2002

Examiner: Raymond, Richard L.

For: Chemical Compounds

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Notice of Co-Pending Applications

The Examiner is hereby requested to take notice of the following co-pending applications, all of which are jointly owned with the instant case.

<u>U.S. Serial No.</u>	<u>U.S. Filing Date</u>
10/637,825	August 8, 2002
10/838,838	May 4, 2004
10/398,264	July 29, 2003
10/472,971	March 25, 2004
10/473,195	February 26, 2004
10/486,479	July 7, 2002

☒ Copies of the references listed on the attached form PTO-1449 are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: August 6, 2004

Marjorie J. Pfeiffer

08/12/2004 YPOLITE1 00000029 071392 10089964

01 FC:1806 180.00 DA

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**


- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan
Attorney for Applicant
Registration No. 38,181

Date: August 6, 2004

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222

Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; margin: 0 auto; display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;"> PI 3806 AUG 12 2004 <small>PATENT & TRADEMARK OFFICE</small> </div> </div>				ATTORNEY DOCKET NO. PI3806USw		SERIAL NO. 10/089,964	
				APPLICANT Giuseppe ALVARO et al.			
				FILING DATE May 8, 2002		GROUP 1624	
				U.S. PATENT DOCUMENTS			
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1.	EP 0655442	05/31/1995	EPO			
	2.	WO 97/16440	05/09/1997	WIPO			
	3.	WO 97/32865	09/12/1997	WIPO			
	4.	WO 98/57954	12/23/1998	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							